Devazepide (CAS 103420-77-5)

Devazepide, a novel synthetic peptide, has emerged as useful in scientific research. Its applications span various in vivo and in vitro experiments, showcasing its effectiveness in numerous biological activities and yielding biochemical and physiological effects. As a non-peptide antagonist of CCK (cholecystokinin) receptors, Devazepide interacts with CCK, a neuroendocrine peptide known for its involvement in cell growth, proliferation, and other vital functions. Notably, Devazepide has demonstrated the induction of apoptosis in Ewing tumor growth studies and has shown an inability to reverse the blocking effect of IL-1β in rat studies. Moreover, it has been reported to inhibit the growth of HT29-S-B6 cells and impact their morphology. Devazepide exerts diverse biochemical and physiological effects, including the modulation of hormone levels like cortisol and testosterone, as well as neurotransmitters such as serotonin and dopamine. While the exact mechanism of action remains incompletely understood, it is postulated that Devazepide may function as an agonist at specific receptors within the body. Additionally, its interaction with other proteins and enzymes in the body likely contributes to the modulation of their activity.